High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.

ABSTRACT: Resistance to Immune Checkpoint Blockade (ICB) constitutes the current limiting factor for the optimal implementation of this novel therapy, which otherwise demonstrates durable responses with acceptable toxicity scores. This limitation is exacerbated by a lack of robust biomarkers. In this study, we have dissected the basal TME composition at the gene expression and cellular levels that predict response to Nivolumab and prognosis. BCR, TCR and HLA profiling were employed for further characterization of the molecular variables associated with response. The findings were validated using a single-cell RNA-seq data of metastatic melanoma patients treated with ICB, and by multispectral immunofluorescence. Finally, machine learning was employed to construct a prediction algorithm that was valid

SUBMITTER: Onieva JL 

PROVIDER: S-EPMC9408876 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature